دورية أكاديمية
A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
| العنوان: | A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03) |
|---|---|
| المؤلفون: | Lee, Dae-Won, Keam, Bhumsuk, Lee, Keun Seok, Ahn, Jin-Hee, Sohn, Joohyuk, Ahn, Jin Seok, Lee, Moon Hee, Kim, Jee Hyun, Lee, Kyung Eun, Kim, Hyo Jung, Kim, Si-Young, Park, Yeon Hee, Ock, Chan-Young, Lee, Kyung-Hun, Han, Sae-Won, Kim, Sung-Bae, Im, Young Hyuck, Chung, Hyun Cheol, Oh, Do-Youn, Im, Seock-Ah |
| المساهمون: | Oh, Do-Youn, Im, Seock-Ah |
| بيانات النشر: | 대한암학회 |
| سنة النشر: | 2023 |
| المجموعة: | Seoul National University: S-Space |
| مصطلحات موضوعية: | CAPECITABINE, LEUCOVORIN, 5-FLUOROURACIL, FLUOROURACIL, CHEMOTHERAPY, MULTICENTER, GUIDELINES, WOMEN, Breast neoplasms, Drug therapy, Oxaliplatin, Phase II trial, S-1 |
| الوصف: | PURPOSE: This single-arm phase II trial investigate the efficacy and safety of S-1 plus oxaliplatin (SOX) in patients with metastatic breast cancer. Materials and Methods: Patients with metastatic breast cancer previously treated with anthracyclines and taxanes were enrolled. Patients received S-1 (40-60 mg depending on patient's body surface area, twice a day, day 1-14) and oxaliplatin (130 mg/m2, day 1) in 3 weeks cycle until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumor 1.1. Secondary endpoints included time-to-progression (TTP), duration-of-response (DoR), overall survival (OS), and adverse events. RESULTS: A total of 87 patients were enrolled from 11 institutions in Korea. Hormone receptor was positive in 54 (62.1%) patients and six (6.9%) had human epidermal growth factor receptor 2-positive disease. Forty-eight patients (85.1%) had visceral metastasis and 74 (55.2%) had more than three sites of metastases. The ORR of SOX regimen was 38.5% (95% confidence interval [CI], 26.9 to 50.0) with a median TTP of 6.0 months (95% CI, 5.1 to 6.9). Median DoR and OS were 10.3 months (95% CI, 5.5 to 15.1) and 19.4 (95% CI, not estimated) months, respectively. Grade 3 or 4 neutropenia was reported in 28 patients (32.1%) and thrombocytopenia was observed in 23 patients (26.6%). CONCLUSION: This phase II study showed that SOX regimen is a reasonable option in metastatic breast cancer previously treated with anthracyclines and taxanes. ; Y ; 1 |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| تدمد: | 1598-2998 |
| العلاقة: | Cancer Research and Treatment, Vol.55 No.2, pp.523-530; https://hdl.handle.net/10371/192432Test; 000981654700016; 2-s2.0-85152477725; 183021; ART002949164 |
| DOI: | 10.4143/crt.2022.1360 |
| الإتاحة: | https://doi.org/10.4143/crt.2022.1360Test https://hdl.handle.net/10371/192432Test |
| رقم الانضمام: | edsbas.2CBAB83C |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 15982998 |
|---|---|
| DOI: | 10.4143/crt.2022.1360 |